CDT Equity expands multi-pathway value creation strategy across pharma, IP

CDT Equity (CDT) provides a strategic update outlining its positioning as a multi-pathway value creation business spanning a pharmaceutical asset portfolio, proprietary solid-form intellectual property and artificial intelligence-driven indication discovery. CDT continues to evaluate and advance its portfolio of assets licensed from AstraZeneca (AZN), including AZD1656, AZD5658 and AZD5904, which benefit from extensive clinical validation and established safety profiles, through combination therapies and novel indications. These assets are a strong foundation for partnership, supported by CDT’s ongoing solid-form and cocrystal innovation programs designed to enhance physicochemical properties and extend patent life.